September 12, 2025ERJ Open ResearchOpen Access

Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis: Findings from ISABELA Clinical Trials

View Full Paper

Ask AI

Bookmark

Patients with higher baseline MMP-7 levels show an annual decline in pulmonary function, indicating disease progression.
Median baseline MMP-7 was significantly higher in patients with a decline in FVC, highlighting its prognostic value.
Machine learning identified changes in CCL18 as a predictor of disease progression at multiple time points in the ISABELA trials.
The combination of elevated biomarkers assists in enhancing the monitoring and assessment of clinical trial efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Analysis shows prognostic biomarkers MMP-7 and CCL18 predict worse outcomes in idiopathic pulmonary fibrosis, indicating their potential for risk stratification.

Cite This Study

Randall et al. (2025) studied this question.

synapsesocial.com/papers/68d418e1713b0b5dfea64da5 https://doi.org/10.1183/23120541.00893-2025

View Full Paper

Ask AI

Bookmark

Implication

Analysis shows prognostic biomarkers MMP-7 and CCL18 predict worse outcomes in idiopathic pulmonary fibrosis, indicating their potential for risk stratification.

Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis: Findings from ISABELA Clinical Trials

Key Points

Discussion

Implication

Cite This Study

Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis: Findings from ISABELA Clinical Trials

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider